A review of allergen immunotherapy in asthma - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles Allergy and Asthma Proceedings Year : 2022

A review of allergen immunotherapy in asthma


Asthma is one of the most common chronic diseases worldwide. Besides symptomatic treatments, allergen immunotherapy (AIT) is a possible add-on treatment for asthmatic patients. In case of an immunologically proven allergen-driven mechanism of asthma, AIT represents the only etiologic treatment for allergic symptoms. AIT has proven both its efficacy and effectiveness in reducing asthma symptoms and asthma medications. It is still debated whether its prescription in severe asthmatic patients is allowed and safe. As for uncontrolled asthma, such a condition should be considered temporary, and AIT may be started as asthma becomes at least partially controlled after treatment adjustment. Finally, randomized trials and real-life studies in recent years have proven that AIT could be administered as a preventive strategy to reduce the risk of developing asthma in patients suffering from allergic rhinitis. More studies are needed to provide more precise indications on the role in clinical practice of AIT in asthmatic patients. Nevertheless, present data are already strong enough to highlight its role as a therapeutic option for allergic asthma and as a preventive strategy to stop or at least decelerate the allergic march.
No file

Dates and versions

hal-03936077 , version 1 (12-01-2023)



D. Caimmi, P Demoly. A review of allergen immunotherapy in asthma. Allergy and Asthma Proceedings, 2022, 43 (4), pp.310-313. ⟨10.2500/aap.2022.43.210113⟩. ⟨hal-03936077⟩
16 View
0 Download



Gmail Facebook X LinkedIn More